PRO1107 in Patients With Advanced Solid Tumors
Genmab
Genmab
Ocellaris Pharma, Inc.
Bolt Biotherapeutics, Inc.
Numab Therapeutics AG
NuCana plc
Seagen Inc.
Sotio Biotech Inc.
Novartis
Novartis
ADC Therapeutics S.A.
Ikena Oncology
Atreca, Inc.
Fate Therapeutics
Fate Therapeutics
Fred Hutchinson Cancer Center
Genmab
Genmab
Nektar Therapeutics
Rubius Therapeutics
Duke University
Calithera Biosciences, Inc
Incyte Corporation
Eli Lilly and Company
Tocagen Inc.
Celldex Therapeutics